References
- Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83:1022–1024.
- Filippini G, Del GC, Clerico M, et al. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane Database Syst Rev. 2017;4:CD012200.
- Ernstsson O, Gyllensten H, Alexanderson K, et al. Cost of illness of multiple sclerosis - a systematic review. PLoS One. 2016;11:e0159129.
- Zaprutko T, Kopciuch D, Kus K, et al. Affordability of medicines in the European Union. PLoS One. 2017;12:e0172753.
- Comi G, Hartung HP, Kurukulasuriya NC, et al. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Pharmacother. 2013;14:123–136.
- Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016;354:i3518.
- Torkildsen O, Myhr KM, Bo L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol. 2016;23(Suppl 1):18–27.
- Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209–220.
- Major EO, Nath A. A link between long-term natalizumab dosing in MS and PML: putting the puzzle together. Neurol Neuroimmunol Neuroinflamm. 2016;3:e235.
- Holmoy T, Von Der LH, Leegaard TM. Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies. BMC Neurol. 2017;17:65.
- Willis MD, Harding KE, Pickersgill TP, et al. Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort. Mult Scler. 2016;22:1215–1223.
- Giovannoni G, Kappos L, Gold R, et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies. Mult Scler Relat Disord. 2016;9:36–46.
- Ghadiri M, Rezk A, Li R, et al. Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol Neuroimmunol Neuroinflamm. 2017;4:e340.
- Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59–63.
- Larochelle C, Metz I, Lecuyer MA, et al. Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal. Mult Scler. 2016;23:72–81.
- Hatcher SE, Waubant E, Nourbakhsh B, et al. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016;73:790–794.
- Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord. 2016;9:198–210.
- Hartung DM, Bourdette DN, Ahmed SM, et al. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Neurology. 2015;84:2185–2192.
- Sorensen PS. Multiple sclerosis. Generic glatiramer acetate–a step toward cheaper MS drugs? Nat Rev Neurol. 2016;12:5–6.
- Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet. 1992;340:952–956.
- Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet. 1997;32:120–131.
- Beutler E, Koziol JA, McMillan R, et al. Marrow suppression produced by repeated doses of cladribine. Acta Haematol. 1994;91:10–15.
- Mitosek-Szewczyk K, Tabarkiewicz J, Wilczynska B, et al. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis. J Neurol Sci. 2013;332:35–40.
- Carson DA, Wasson DB, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983;62:737–743.
- Gorski A, Grieb P, Makula J, et al. 2-Chloro-2-deoxyadenosine–a novel immunosuppressive agent. Transplantation. 1993;56:1253–1257.
- Baker D, Marta M, Pryce G, et al. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine. 2017;16:41–50.
- Baker D, Herrod SS, Alvarez-Gonzalez C, et al. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4:e360.
- Janssen-Cilag Ltd. Leustat Injection. Summary of Product Characteristics. [updated 2014 Jul; cited 2017 Jun]. https://www.medicines.org.uk/emc/medicine/6737
- Laugel B, Borlat F, Galibert L, et al. Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity. J Neuroimmunol. 2011;240-241:52–57.
- Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 1994;344:9–13.
- Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A. 1996;93:1716–1720.
- Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians. 1999;111:35–44.
- Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI study group. Neurology. 2000;54:1145–1155.
- Stelmasiak Z, Solski J, Nowicki J, et al. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. Mult Scler. 2009;15:767–770.
- Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–426.
- Leist TP, Comi G, Cree BA, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13:257–267.
- Korsen M, Bragado AS, Peix L, et al. Cladribine exposure results in a sustained modulation of the cytokine response in human peripheral blood mononuclear cells. PLoS ONE. 2015;10:e0129182.
- Musella A, Mandolesi G, Gentile A, et al. Cladribine interferes with IL-1beta synaptic effects in experimental multiple sclerosis. J Neuroimmunol. 2013;264:8–13.
- Lindemalm S, Liliemark J, Juliusson G, et al. Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Cancer Lett. 2004;210:171–177.
- Savic RM, Novakovic AM, Ekblom M, et al. Population pharmacokinetics of cladribine in patients with multiple sclerosis. Clin Pharmacokinet. 2017. DOI:10.1007/s40262-017-0516-6
- Saven A, Kawasaki H, Carrera CJ, et al. 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J Clin Oncol. 1993;11:671–678.
- Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother. 2005;5:721–727.
- Beutler E, Sipe J, Romine J, et al. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin Hematol. 1996;33:45–52.
- Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227–231.
- Sipe JC, Romine JS, Koziol JA, et al. Development of cladribine treatment in multiple sclerosis. Mult Scler. 1996;1:343–347.
- Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials in multiple sclerosis: rewport by the panel on evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122:552–568.
- McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–127.
- Fazekas F, Barkhof F, Filippi M, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology. 1999;53:448–456.
- National Institutes of Health, Clinicaltrials.com. CLARITY extension study. [updated 2014 Jan 24; cited 2014 Aug 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT00641537?term=cladribine+and+multiple+sclerosis&rank=6.
- Giovannoni G, Comi G, Cook S, et al. Clinical efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week phase IIIb extension trial to the CLARITY study. Neurology. 2016;86(16 Suppl):P3.028.
- Comi G, Giovannoni G, Cook S, et al. Magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets: results from the 120-week phase IIIb extension of the CLARITY study. Neurology. 2016;86(16 Suppl):P2.11.
- De Stefano N, Giorgio A, Battaglini M, et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler. 2017. 1352458517690269.
- Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–846.
- National Institutes of Health, Clinicaltrials.com. A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD). [updated 2013 Aug 4; cited 2017 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT00436826?term=cladribine+and+multiple+sclerosis&rank=3
- Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials (PREMIERE). [updated 2017 Aug 9; cited 2017 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01013350
- Cook S, Vermersch P, Comi G, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler. 2011;17:578–593.
- Uppsala Monitoring Centre. VigiBase, the World Health Organization (WHO) international database of suspected adverse drug reactions. [cited 2017 Jul 12]. Available from: https://www.who-umc.org/vigibase/vigibase/.
- Lorvik KB, Bogen B, Corthay A. Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood. 2012;119:2176–2177.
- European Medicines Agency, Committee for Medical Products for Human Use 2011. Withdrawal assessment report for Movectro. [ cited 2017 May 24]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2011/03/WC500104393.pdf
- Pakpoor J, Disanto G, Altmann DR, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015;2:e158.
- European Medicines Agency, Commmittee for Medical Products for Human Use 2017. Summary of opinion (initial authorisation) Mavenclad cladribine. [cited 2017 Jul 12]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004230/smops/Positive/human_smop_001150.jsp&mid=WC0b01ac058001d127
- Drugsite Trust, breastfeeding. Cladribine Pregnancy and breastfeeding Warnings 2017. [cited 2017 Jul 12]. Available from: https://www.drugs.com/cdi/cladribine.html
- Drugsite Trust, Drugs.com 2017. Cladribine approval status. 2017. [cited 2017 Jul 12]. Available from: https://www.drugs.com/history/cladribine.html
- European Medicines Agency, Committee for Medical Products for Human Use 2011. Refusal of the marketing authorisation for Movectro (cladribine). [cited 2017 Jul 12]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/001197/WC500101072.pdf
- Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 2011;10:1026–1034.
- EMD Seono 2016. Merck KGaA, Darmstadt, Germany Receives European Medicines Agency Acceptance for Review of Marketing Authorization Application for Cladribine Tablets. Press release. [cited 2017 Jul 12]. Available from: http://www.merckgroup.com/en/media/extNewsDetail.html?newsId=57F6B32E5CD8E3AAC1257FF100307005&newsType=1
- Stangel M, Penner IK, Kallmann BA, et al. Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord. 2015;8:3–13.
- Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10:329–337.
- Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–234.
- Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–260.
- Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–1839.
- Damasceno A, Damasceno BP, Cendes F. No evidence of disease activity in multiple sclerosis: implications on cognition and brain atrophy. Mult Scler. 2016;22:64–72.
- Biogen Idec 2017. Tysabri Prescribing Information. [ cited 2017 Aug 17]. Available from: https://www.tysabrihcp.com/en_us/home/safety/risk-pml-jcv.html
- Penkert H, Delbridge C, Wantia N, et al. Fulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosis. JAMA Neurol. 2016;73:757–759.
- Clerico M, De MS, Artusi CA, et al. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab. Mult Scler. 2017;23:874–876.
- Brownlee WJ, Chataway J. Opportunistic infections after alemtuzumab: new cases of norcardial infection and cytomegalovirus syndrome. Mult Scler. 2017;23:876–877.
- Bittner S, Ruck T, Wiendl H, et al. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017;10:51–66.
- Sormani MP, Muraro PA, Saccardi R, et al. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs. Mult Scler. 2017;23:201–204.